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https://doi.org/10.1016/j.stemcr.2020.05.002SUMMARYStudies of patients with acutemyeloid leukemia (AML) have led to the identification of mutations that affect different cellular pathways.
Some of these have been classified as preleukemic, and a stepwise evolution programwhereby cells acquire additionalmutations has been
proposed in the development of AML. How the timing of acquisition of these mutations and their impact on transformation and the
bone marrow (BM) microenvironment occurs has only recently begun to be investigated. We show that constitutive and early loss of
the epigenetic regulator, TET2, when combined with constitutive activation of FLT3, results in transformation of chronic myelomono-
cytic leukemia-like ormyeloproliferative neoplasm-like phenotype to AML,which ismore pronounced in double-mutantmice relative to
mice carrying mutations in single genes. Furthermore, we show that in preleukemic and leukemic mice there are alterations in the BM
niche and secreted cytokines, which creates a permissive environment for the growth of mutation-bearing cells relative to normal cells.INTRODUCTION
Hematopoiesis is a tightly regulated process whereby all the
blood cells arise from a pluripotent stem cell population.
However, several mutations in hematopoietic stem cells
have been identified that lead to deregulation of cellular
differentiation and proliferation. In acute myeloid leuke-
mia (AML), both chromosomal abnormalities and single
gene mutations have been described to play a role in dis-
ease initiation, progression, and prognosis. Within the
cytogenetically normal patients, mutations in genes that
regulate DNA methylation including IDH, DNMT3A
(20%–25%), and TET2 (20%) have been thought to occur
early on during leukemogenesis (Abdel-Wahab and Levine,
2013; Cagnetta et al., 2014; Ley et al., 2010; Frohling et al.,
2002). These loss-of-function mutations result in impaired
differentiation and enhance the self-renewal of hemato-
poietic stem cells in mouse models can result in the devel-
opment of chronic myelomonocytic leukemia (CMML)-
like and myeloproliferative neoplasm (MPN)-like disease.
Subsequent acquisition of additional mutations that pro-
vide proliferation and/or survival advantage to these pre-
leukemic clones are required for their transformation to
AML. One of the common mutation partners is Fms-like
tyrosine kinase 3 (FLT3) with internal tandem duplication
(ITD), leading to constitutive activation of this receptor
tyrosine kinase. FLT3-ITD is present in 30% of AML pa-
tients and is considered an independent prognosticmarker.
AML patients with mutations in DNA-methylation regula-Stem
This is an open access article under the Ctors and FLT3-ITD constitute a poor prognosis group and
often do not respond to conventional chemotherapy or ki-
nase-targeted therapies (Kottaridis et al., 2001). Absence of
relevant mouse models has hampered the progress in iden-
tifying the molecular approaches that will have better out-
comes for these patients. To this end, we generated mice
that co-express these mutations to find out whether they
are sufficient for transformation from a CMML- and
MPN-like disease to AML to obtain a better understanding
of the earliest hematopoietic cells in the hierarchy to be
affected.
TET methylcytosine dioxygenase 2 (TET2) plays an
essential role in regulating the conversion of 5-methylcyto-
sine to 5-hydroxymethylcytosine, which functions as an
intermediate step for DNA demethylation. Loss of Tet2
function is associated with increased promoter methyl-
ation and aberrant expansion of myeloid cells in different
mouse models. The myeloid progenitor cells in Tet2
mutant mice show impaired differentiation and demon-
strate higher engraftment in transplant studies, indicating
an increase in stem cell self-renewal abilities (Li et al.,
2011). On the other hand, FLT3ITD knockin mice show
increased proliferation of hematopoietic stem cells, leading
to increased numbers of myeloid cells (Lee et al., 2007). In
contrast to the Tet2/ mice, Flt3ITD/ITD mice show defects
in the competitive transplant setting, as stem cells derived
from these mice are highly proliferative. Both of these mu-
tations lead to expansion of themyeloid compartment, but
the mice with single mutations do not develop AML.Cell Reports j Vol. 15 j 95–109 j July 14, 2020 j ª 2020 The Author(s). 95
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
To mimic the co-occurrence and timing of expression of
these twomutations inAMLpatients, we intercrossed these
mice to bring the two mutations together and found that
the double-mutantmice develop AMLwith complete pene-
trance and a short latency period. The transformation of
CMML/MPN to AML occurred irrespective of the dosage
of the two mutations.
While loss of Tet2 and presence of Flt3ITD in hematopoi-
etic stem/progenitor cells (HSC/Ps) was capable of trans-
forming hematopoietic stem cells in a cell-autonomous
manner, we also found that the bone marrow (BM) niche
plays an important role in regulating hematopoietic stem
cell (HSC) behavior, which was significantly altered in the
leukemic and preleukemic mice. Several recent studies
(Duan et al., 2014; Forman and Rowe, 2013; Sanchez-Cor-
rea et al., 2013) have suggested that the BMmicroenviron-
ment contributes to the clinical outcomes in MPN and
AML patients by contributing to drug resistance. Alter-
ations in the these BM niche cells results in changes in
the milieu of soluble factors, and the newly acquired
cellular composition can activate aberrant proliferation
and migration of HSCs, leading to expansion of myeloid
cells even in the absence of any mutations in HSCs
(Schepers et al., 2013). Thus, the BM microenvironment
not only protects leukemic cells from drugs but can also
promote leukemogenesis in transplanted donor cells, ac-
counting for disease relapse and donor-derived leukemia.
Our mouse model shows that presence of germline muta-
tions in Tet2 and FLT3ITD not only deregulates hematopoi-
esis at the earliest stem cell stage but also distorts the
composition and solublemilieu of the BMniche to support
the growth and survival of leukemic cells. Some of these
changes in the BM niche become apparent in preleukemic
mice that have loss of TET2 and are capable of promoting
myeloid bias and expansion of even normal non-mutated
hematopoietic cells. In summary, we describe physiologi-
cally relevant models of AML that are likely to have better
predictive value for drug testing studies, and provide
more information on essential features for transformation
of CMML/MPN to AML.RESULTS
Loss of Tet2 Followed by Expression of Flt3ITD/ITD in
BM Cells Leads to Development of Fatal AML
In humans,mutations in DNA-methylation regulator TET2
occur early on in preleukemic cells followed by acquisition
of additional mutations, leading to the development of
full-blown AML (Sato et al., 2016; Wakita et al., 2013;
Weissmann et al., 2012). FLT3ITD/ITD is one such common
mutation that occurs subsequent to the acquisition of
TET2 mutations in humans (Tian et al., 2014; Wakita96 Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020et al., 2013). However, it is unclear as to which cell-auton-
omous and non-autonomous changes take place when
TET2 is lost early in development in H2SC/Ps prior to the
acquisition of FLT3ITD/ITD. To study this, we intercrossed
Tet2/ (global knockout of Tet2) mice with Flt3ITD/ITD-ex-
pressing mice (specifically expressed in hematopoietic
cells) to generate Tet2/:Flt3ITD/ITD compound mutant
mice. Tet2/:Flt3ITD/ITD mice showed significantly shorter
survival compared with wild type (WT) or the single mu-
tants of Tet2/ or Flt3ITD/ITD (Figure 1A). Although the sur-
vival data for the single-mutant mice is consistent with the
published literature demonstrating development of
CMML-like disease with a median survival of over a year
(Li et al., 2011; Lee et al., 2007), the median survival of
Tet2/:Flt3ITD/ITD mice was significantly reduced with all
mice dead within 5 months post birth (Figure 1A). To
further characterize Tet2/:Flt3ITD/ITD mutant mice, we
analyzed hematopoietic tissues of these mice at
4 months post birth, as the majority of these mice began
to succumb around this time. White blood cell (WBC)
counts and spleen size were significantly elevated in
Tet2/:Flt3ITD/ITD mutant mice compared with all the
other groups, with neutrophils and monocytes being the
major cell type responsible for elevated WBC counts (Fig-
ures 1B–1D). Importantly, only Tet2/:Flt3ITD/ITD com-
pound mutant mice showed a significant increase in
KIT+CD11b+ myeloid blasts, suggesting that early loss of
Tet2 and acquisition of Flt3ITD/ITD rapidly transforms pre-
leukemic cells into AML (Figures 1E and 1F). Histopatho-
logical examination of BM, spleen, and liver further
confirmed these observations as reflected by an increase
in myeloid cell infiltration and loss of tissue architecture
(Figure S1). Neither Tet2/ nor Flt3ITD/ITD mice by them-
selves led to such profound changes within this time
span. Thus, early loss of Tet2 with subsequent acquisition
of Flt3ITD/ITD is capable of transforming preleukemic HSC/
Ps into AML with a short latency period.
Tet2/:Flt3ITD/ITD Mice Show an Increase in BM
Cellularity, Expansion of Myeloid Cell Compartment,
and Defects in Maturation
Since various peripheral hematopoietic compartments
showed a significant expansion of myeloid cells in
Tet2/:Flt3ITD/ITD mice, we next examined whether this
was observed in the BMaswell. Consistent with the BMhy-
percellularity observed during the histopathological exam-
ination of Tet2/:Flt3ITD/ITD mice, the total number of
mononuclear cells were also significantly higher in
Flt3ITD/ITD and Tet2/:Flt3ITD/ITD mice compared with
WT mice, with Tet2/:Flt3ITD/ITD mutant mice showing
the greatest number of cells in the BM (Figure 2A). Increase
in BM cellularity was accompanied with an increase in the
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Figure 1. Loss of Tet2 with Concomitant
Expression of Flt3ITD/ITD in Mice Leads to
Development of Fatal AML with a Short La-
tency Period
(A) Kaplan-Meier survival curve for WT (n =
6), Tet2/ (n = 7), Flt3ITD/ITD (n = 7), and
Tet2/:Flt3ITD/ITD (n = 10) mice.
(B) Changes in peripheral blood counts of (i)
WBCs, (ii) neutrophils, (iii) lymphocytes, (iv)
monocytes, and (iv) RBCs (n = 6–7 mice per
group).
(C–F) (C) Spleen pictures and (D) Quantifi-
cation of spleen weight (in grams) of 4-
month-old WT, Tet2/, Flt3ITD/ITD, and
Tet2/:Flt3ITD/ITD mice (n = 6–7 mice per
group). (E) Frequency of myeloid blasts in
spleen (n = 3 mice per group). (F) Repre-
sentative flow profiles of splenic myeloid
blasts expressing C-KIT/CD11b.
Data were collected from two independent
experiments. See also Figure S1.single-positive myeloid cells (Figures 2B and 2C), with a
concomitant reduction in B220/CD19 double-positive B
cells (Figures 2D and 2E) in Tet2/:Flt3ITD/ITD mice relative
to other genotypes. While in WT the majority of BM
myeloid cells were of a mature CD11b+GR1+ phenotype,
in the Flt3ITD/ITD and Tet2/:Flt3ITD/ITD mice there was a
significant increase in both the absolute number and fre-
quency of cells that expressed only CD11b or GR1, and
this phenotypewasmore pronounced inTet2/:Flt3ITD/ITD
mice (Figures 2B, 2C, and 2G). Additionally, erythroid fre-
quency of single-positive CD71 was found to be increased
in Flt3
ITD/ITD
and Tet2/:Flt3ITD/ITD mice, with greater
frequency in the Tet2/:Flt3ITD/ITD mutant mice
compared with Flt3ITD/ITD mice (Figures 2F and 2G). While
both of these groups showed a reduction in the
development of mature Ter119+ erythroid cells (Figures
2G and 2F), accounting for the observed reduction in pe-ripheral red blood cells (RBCs) (Figure 1), it was only in
Tet2/:Flt3ITD/ITD mice that a significantly decreased at
pro-erythroblast (CD71+) stage was observed (Figures 2F
and 2G). Similarly, development of B-lineage cells was
severely affected by the presence of Flt3ITD/ITD mutation,
which is consistent with the published literature (Lee
et al., 2007). These results demonstrate that loss of Tet2 fol-
lowed by expression of Flt3ITD/ITD in BM cells results in sig-
nificant alterations in the maturation of multiple lineages
including myeloid, erythroid, and lymphoid.
Tet2/:Flt3ITD/ITD Mice Show Alterations in the
Composition of Primitive Stemand Progenitor Cells in
the BM
In an effort to assess how loss of Tet2 followed by the
expression of Flt3ITD/ITD affects the composition of more
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Figure 2. Tet2/:Flt3ITD/ITD Mice Show
Significant Increase in Bone Marrow Cellu-
larity and Expansion of Myeloid Cell
Compartment
Bone marrow from 4-month-old WT, Tet2/,
Flt3ITD/ITD, and Tet2/:Flt3ITD/ITD mice were
analyzed for committed mature cells by flow
cytometry as described in Experimental Pro-
cedures.
(A–C) (A) Bone marrow cellularity (n = 6–7
mice per group). (B) Frequency of (i) CD11b+,
(ii) Gr1+/CD11b+, and (iii) Gr1+ myeloid cells
in bone marrow (n = 4–6 mice per group). (C)
Number of (i) CD11b+, (ii) Gr1+/CD11b+, and
(iii) Gr1+ myeloid cells in bone marrow (n =
4–6 mice per group).
(D–F) (D) (i) Frequency of B220+ and (ii)
B220+/CD19+ lymphoid cells in bone marrow
(n = 4–6 mice per group). (E) (i) Number of
B220+ and (ii) B220+/CD19+ lymphoid cells in
bone marrow (n = 4–6 mice per group). (F) (i)
Frequency of CD71+, (ii) Ter119+/CD71+, and
(iii) Ter119+ cells in bone marrow (n = 4–6
mice per group).
(G) Representative flow profiles of erythroid,
myeloid, and B cells in the bone marrow of
indicated genotypes.the BM of Tet2/:Flt3ITD/ITD mice. Both the absolute num-
ber and the frequency of LinKit+sca1 (LSK) fraction of
the BM cells, which is enriched in hematopoietic stem
cells, was significantly expanded in all threemutantmouse
groups compared with WT controls. However, the magni-
tude of expansion of LSK cells was most dramatically
altered in the BM and spleen of Tet2/: Flt3ITD/ITD mice
relative to other genotypes (Figures 3A–3D). The most pro-
found changes were observed in Tet2/: Flt3ITD/ITD mice.
The BM of these mice showed an almost complete loss of
long-term (LT)-HSCs (CD48CD150+LSK) accompanied
by an increase in short-term HSCs (CD48+CD150LSK)
(Figures 3E–3G). Thus, differentiation blockade caused by98 Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020the combination of these mutations possibly exerts its ef-
fects at different stages of hematopoiesis.
Heterozygous Loss of Tet2 and Expression of
Heterozygous Flt3ITD/+ or Homozygous Flt3ITD/ITD in
BM Stem and Progenitor Cells Results in the
Development of AML butwith DelayedOnset and Less
Severity
In a subset of AML patients, often heterozygosity of Tet2
along with heterozygous presence of Flt3ITD/+ is observed
(Tefferi et al., 2009). How Tet2 heterozygosity as opposed
to Tet2 homozygosity cooperates with the expression of







































































































Figure 3. Development of AML in
Tet2/:Flt3ITD/ITD Mice Is Due to Expan-
sion of LSK Cells
Bone marrow and spleens were harvested
from 4-month-old WT, Tet2/, Flt3ITD/ITD,
and Tet2/:Flt3ITD/ITD mice and analyzed for
stem and progenitor cells by flow cytometry
as described in Experimental Procedures.
(A and B) (A) Frequency and (B) absolute
number of Lin-Sca1+KIT+ (LSK) cells in the
bone marrow (n = 4–6 mice per group).
(C) Representative flow profiles of LSK cells in
the bone marrow of indicated genotypes.
(D) Frequency of LSK cells in the spleen of
indicated genotypes (n = 3–5 mice per
group).
(E and F) (E) Frequency and (F) absolute
number of CD48CD150+LSK cells in the bone
marrow of indicated genotypes (n = 3 mice
per group).
(G) Representative flow profiles of
CD48CD150+LSK cells in the bone marrow of
indicated genotypes (n = 3 mice per group).generated mice of six different genotypes, namely WT,
Tet2+/, Flt3ITD/+, Flt3ITD/ITD, Tet2+/:Flt3ITD/+, and
Tet2+/:Flt3ITD/ITD. At 4 months of age, we analyzed these
mice for peripheral blood counts. As seen in Figure S2A,
no significant differences were observed in peripheral
blood parameters between any of the four groups of mice
involving Tet2+/:Flt3ITD/+. In contrast, Tet2+/:Flt3ITD/ITD
mice demonstrated a significant increase in both neutro-
phil and monocyte counts relative to rest of the
genotypes in this group (Figure S2B). Both Flt3ITD/ITD and
Tet2+/:Flt3ITD/ITD mice demonstrated a significant reduc-
tion in peripheral RBC counts relative to other
genotypes (Figure S2B). BM analysis revealed a significant
increase in cellularity in Tet2+/:Flt3ITD/+, Flt3ITD/ITD, andTet2+/:Flt3ITD/ITD mice compared with WT or Tet2+/
mice (Figures S2C and S2D). A significant increase in spleen
weight in both Tet2+/:Flt3ITD/+ and Tet2+/:Flt3ITD/ITDmice
was also observed relative to control mice (Figures S2E and
S2F).Wenext analyzed the frequency and absolute number
of LSK cells in the BMof all six genotypes. As seen in Figures
S3A–S3D, the greatest increase in the absolute number of
LSK cells was seen in Tet2+/:Flt3ITD/+ and Tet2+/:Flt3ITD/ITD
mice relative to other groups. We also examined erythroid
and myeloid cells in the BM of six genotypes and observed
the greatest increase in the frequency of CD71-positive
erythroid cells inTet2
+/
:Flt3ITD/ITDmice relative to other ge-
notypes (Figure S4). Similar observations were made in the
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the changes in the size and distribution of various HSC/Ps
and mature cells in the BM, spleen, or peripheral
blood were dose dependent and most impressive in
Tet2/:Flt3ITD/ITD, mice followed by Tet2+/:Flt3ITD/ITD
mice and Tet2+/:Flt3ITD/WT mice.
At 8–10 weeks of age, 2 million BM cells from the six ge-
notypes were injected into lethally irradiated recipients,
and the mice were examined for survival. As seen in
Figure 4A, starting on day 120 (4 months) post
transplant, Tet2+/:Flt3ITD/ITD mice began to succumb to
AML and all mice died by 210 days or 7 months post trans-
plant. Figure 4B shows the spleens of WT, Tet2/, and
Tet2+/:Flt3ITD/ITD. We analyzed for non-hematopoietic
components, as shown in Figure 4C, and observed: (1) het-
erozygous loss of Tet2 along with co-occurrence of
Flt3ITD/ITD mutation, showing greater expansion of mesen-
chymal stem cells (MSCs); and (2) significant expansion of
endothelial cells (ECs) in Tet2+/ and a trend toward addi-
tive on co-occurrence with Flt3ITD/ITD mutation. To eval-
uate the functional impact of Tet2 loss alone or in combina-
tion with Flt3ITD (Tet2/:Flt3ITD/+) on osteoclasts, we
performed tartrate-resistant acid phosphatase (TRAP) stain-
ing on femurs from WT, Tet2/, and Tet2/:Flt3ITD/+ pri-
mary mice. As shown in Figure 4D, presence of increased
TRAP staining was observed in Tet2/ and Tet2/:Fl-
t3ITD/+ femurs compared with WT, which also supports
the in vitro TRAP data (Figure 4F, upper panel) and suggests
that osteoclasts potentially contribute to the leukemic
phenotype. Next, we assessed the impact of Tet2/
and Tet2/:Flt3ITD/+ mutations on the development of
osteoblast cells (OBCs) by alkaline phosphatase
assay on cultured cells derived from WT, Tet2/, and
Tet2/:Flt3ITD/+ primary mice. Greater proliferating OB ac-
tivity was found in Tet2/ and Tet2/:Flt3ITD/+ cultures
compared with WT controls, as shown in the lower panels
of Figure 4F. A greater number of monocyte/macrophage
precursors from Tet2/ and Tet2/:Flt3ITD/+ mice might
possibly be contributing to differentiation of cells into oste-Figure 4. Heterozygosity or Homozygosity of Flt3ITD along with Co
with Similar Latency
(A) Primary bone marrow transplantation. Two million bone marro
Tet2+/:Flt3ITD/ITD mice were transplanted into lethally irradiated C5
progression, and Kaplan-Meier survival was established (n = 5 mice p
(B) Pictures of spleens from indicated genotypes. See also Figures S2
(C) Mesenchymal stem cells and endothelial cells were analyzed in pri
Tet2+/, and Tet2+/:Flt3ITD/ITD mice were subjected to collagenase d
LinNeg, CD31Neg, Sca1Pos, CD51Pos), endothelial cells (CD45Neg, LinNeg,
Sca1Neg, CD51Pos). See also Figure S5.
(D) Images of tartrate-resistant acid phosphatase (TRAP) staining o
biological replicates).
(E) Images of Vonkossa staining on femurs from the primary mice of
(F) Representative images of TRAP staining (upper panels) and nitrobl
staining (lower panels) from in vitro cultures of indicated genotypesoclast bone-resorbing cells and greater bone nodule forma-
tion, as shown by Vonkossa staining on femurs, thereby
inducing greater bone remodeling (Figure 4E).
Interestingly, mice transplanted with BM cells derived
from Tet2+/:Flt3ITD/+ mice also began to succumb around
the same time as Tet2+/:Flt3ITD/ITD mice, and all were
dead by 7 months (Figure S3E). At 4 months post primary
transplant, BM cells derived from the primary transplanted
recipients were transplanted into lethally irradiated sec-
ondary hosts. As seen in Figures S3F and S3G, these recipi-
ents began to succumb around day 90 (3 months), and all
mice were dead by 160 days (5 months). These results illus-
trate that haploinsufficiency or homozygosity of Flt3ITD co-
operates equally well with Tet2 heterozygosity in the devel-
opment of AML and overall survival.
Loss of Tet2 Alters the BM Microenvironment and
Produces More Pro-inflammatory Cytokines
There is increasing evidence (Guarnerio et al., 2018; Schepers
et al., 2013) of crosstalk between leukemic cells and their
microenvironment whereby both can modulate each other
to support the survival of leukemic cells and disease develop-
ment. We next assessed the BM composition of Tet2/ mice
by examining the frequency of MSCs, ECs, and OBCs, three
cell types that can influence the growth and survival of
both normal and leukemic cells. As seen in Figures 5A–5C, a
significant increase in the frequency of all three cell types
was observed in Tet2/ mice. Furthermore, loss of TET2
also resulted in significant alteration in the expression levels
of various pro-inflammatory cytokines that have been impli-
cated in regulating HSC/P functions including interleukin-5
(IL-5), IL-6andCXCL5,whichwereall elevated intheabsence
of Tet2, andmacrophage inflammatory protein 1A (MIP-1A),
MIP-1B,MIP-2, tumor necrosis factor a (TNFa), IL-13, and IL-
15, which were all downregulated in these mice compared
with controls (Figures 5D–5I). High levels of TNFa are detri-
mental to the propagation of stem cells. A recent study in
Flt3ITD mice (Mead et al., 2017) showed increased levels ofncomitant Heterozygosity of Tet2 Results in AML Development
w mononuclear cells isolated from WT, Tet2+/, Flt3ITD/ITD, and
7BL/6 mice through tail vein injection and monitored for disease
er group). See also Figure S3.
and S4.
mary mice by flow cytometry (n = 3 mice). In brief, bones from WT,
igestion followed by staining for mesenchymal stem cells (CD45Neg,
CD31Pos), and osteoblastic lineage cells (CD45Neg, LinNeg, CD31Neg,
n femurs from the primary mice of the indicated genotypes (n = 3
the indicated genotypes (n = 3 biological replicates).
ue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP)
(n = 3 independent experiments).
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Figure 5. Loss of Tet2 Alters the Composi-
tion of the Bone Marrow Microenviron-
ment and Cytokine Production
(A–C) Bones were harvested from 3-month-
old WT and Tet2/ mice (n = 4–5) and
subjected to collagenase digestion followed
by staining for (A) mesenchymal stem cells,
(B) endothelial cells, and (C) osteoblastic
lineage cells, and analyzed by flow cy-
tometry. Cytokines and chemokines from
serum of 3-month-old WT and Tet2/ mice
were assayed using mouse 32-plex cytokine/
chemokine array.
(D–I) (D) Cxcl5, (E) IL-1a, and (F) IL-5 and
IL-6 were increased and (G) IL-13 and IL-15,
(H) TNFa, and (I) MIP1a, MIP1b, and MIP2
were decreased. Concentrations are pre-
sented in pg/mL (n = 3–5 mice per geno-
type).
Student’s unpaired t test was performed for
statistical significance (*p < 0.05, **p <
0.001).TNFa and its associationwith stemcell exhaustion. Thus, less
TNFa, as seen inourmodel,maycontribute tobetterpropaga-
tion andmaintenance of overall hematopoiesis. IL-13 plays a
critical role in B cellmaturation and differentiation. IL-15 is a
knownmitogen and survival factor for Tcells. In the absence
or inhibition of IL-15, Tcell immunity is likely to be affected.
Studies (Devos et al., 2017; Yu et al., 2015; Harish and
Schwartz, 2020; Ichiyama et al., 2015) demonstrate that
TET2-mediated demethylation controls cytokine expression
in T helper cells. Consistent with this notion, our AMLmice
are likely to have poor anti-tumor immunity due to the pres-
ence of possibly increased numbers of T suppressor cells.
Altered BMMicroenvironment inTet2/MutantMice
Supports the Expansion of Leukemic Cells
Given the nature of changes in the composition of BM
microenvironment in mice bearing loss of TET2, including102 Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020enhanced frequency of MSCs, ECs, and OBCs in addition
to cytokines, we asked whether transplanting normal BM
cells or BM cells derived from mice bearing a key mutation
associated with AML, such as Flt3ITD/ITD into Tet2-deficient
mice, would support the growth of these cells or not. We
took 2 million BM cells from WT or Flt3ITD/ITD mice and
transplanted them into lethally irradiated WT or Tet2/
mice, and monitored the engraftment (Figure 6A). At
5 months post transplant, mice were sacrificed and
analyzed. As seen in Figures 6B and 6C, BM derived from
Flt3ITD/ITDmice, when transplanted into Tet2/ recipients,
resulted in the development of largest spleen size and
weight relative to all other experimental groups. In the
BM, a profound increase in the frequency as well as in
the absolute number of LSK cells was noted when
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Wenext examined the impact ofTet2-deficient recipients
transplanted with WT or Flt3ITD/ITD BM cells to give rise to
more mature myeloid and lymphoid cells. In the BM, we
found a significant increase in the presence of Gr-1/
CD11b double-positive cells when Flt3ITD/ITD cells were
transplanted into Tet2-deficient recipients relative to all
other groups (Figure 6E). Consistent with our findings in
the marrow, a much more pronounced expansion of
Gr-1/CD11b double-positive as well as CD11b single-posi-
tive cells was noted in Tet2/ mice transplanted with
Flt3ITD/ITD BM cells in the spleen (Figure 6G). Representa-
tive flow profiles in the BM and spleen of transplanted
mice in the four experimental groups are shown in Figures
S6A and S6B. We also examined the contribution of B cells
in the four transplanted groups. As seen in Figures 6F and
6H, a significant decrease in the production of B cells was
noted in both the BM and the spleen of Tet2/ recipient
mice transplanted with Flt3ITD/ITD BM cells, as assessed by
the decrease in frequency of B220/CD19 double-positive
cells. A similar finding was observed when Flt3ITD/ITD BM
cells were transplanted into WT recipients. These results
suggest that the defects observed in B cell development
and maturation associated with Flt3ITD/ITD-bearing HSC/
Ps are mainly cell intrinsic and not dependent on the
microenvironment, although a modest but significant
further reduction in the B220/CD19 double-positive
cells was noted in Tet2/ recipients transplanted with
Flt3ITD/ITD cells (Figure 6H).
Tet2-Deficient Myeloid Progenitors Expand in
Recipient Mice Lacking a Combination of Tet2 and
Expressing Flt3ITD/+
To assess how Tet2/ preleukemic BM cells grow in a
microenvironment with AML driven by a combination of
Tet2/:Flt3ITD/+ mutations, we transplanted 2 million BM
cells from 7 to 8month-old Tet2/ mice into lethally irradi-
ated age-matched WT or Tet2/:Flt3ITD/+ mice and moni-
tored the engraftment of donor cells. Six weeks after trans-
plantation, mice were sacrificed on account of moribundFigure 6. Altered Bone Marrow Microenvironment in Preleukem
Flt3ITD/ITD-Bearing Cells
(A) Schematic showing transplantation of normal WT or Flt3ITD/ITD-bea
cells (2 3 106) isolated from WT or Flt3ITD/ITD mice were transplanted
monitored for disease progression. Reconstitution of hematopoietic ste
(B) Photos of representative spleens from transplanted mice.
(C) Spleen weights (6–11 mice in each group).
(D) (i) Representative flow profile of LSK cells in the bone marrow of
cells in the bone marrow.
(E) Bone marrow frequency of indicated genotypes of (i) Gr1+/CD11b
(F) Frequency of (i) B220+/CD19+ and (ii) B220+ in bone marrow of i
(G) Spleen frequency of indicated genotypes of (i) Gr1+/CD11b+, (ii)
(H) Frequency of (i) B220+/CD19+ and (ii) B220+ in spleen of indicat
Data were collected from two independent experiments. See also Figu
104 Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020features. As shown in Figure 7B, phenotypic analysis of BM
cells derived from Tet2/:Flt3ITD/+ recipients showed an
elevated number of myeloid progenitor (GMP) cells relative
to controls. The frequency of mature myeloid Gr1/CD11b
was also increased in the BM (Figure 7C) and spleen (Fig-
ure 7F) of Tet2/:Flt3ITD/+ recipients compared with con-
trols; whereas the frequency of lymphoid cells (B220) was
reduced (Figures 7D and 7G). Figures 7E and 7H show repre-
sentative flow profiles of myeloid and lymphoid cells in
Tet2/:Flt3ITD/+-recipient mice transplanted with Tet2/
cells. Next, we performed coculture assay to assess the rela-
tive contribution of OBCs in supporting the growth of
Tet2/:Flt3ITD/+ cells. As shown in Figure 7I, an increase in
colony-forming units (CFU) was observed when purified
lineage-negative Tet2/:Flt3ITD/+ cells were cocultured with
OBCs derived from Tet2/:Flt3ITD/+ mice compared with
OBCs derived from Tet2/ and/or WT OBCs. Furthermore,
to test whether Tet2/:Flt3ITD/ITD BM supports the survival
of WT cells better than preleukemic Tet2/ cells, we trans-
planted Tet2/:Flt3ITD/ITD cells into WT and Tet2/ recipi-
ents and followed their survival. Four Tet2/ recipients out
of five that were transplanted with Tet2/:Flt3ITD/ITD cells
died 15 days post transplantation and onewasmoribund af-
ter 93 days. None of the WT recipients transplanted with
Tet2/:Flt3ITD/ITD cells were found dead (Figure 7J), suggest-
ing that Tet2/:Flt3ITD/ITD leukemic cells survive better in
the normal WT microenvironment but die when exposed
to the preleukemicTet2/microenvironment. Significantly
elevated peripheral WBCs, neutrophils, lymphocytes, and
monocyte counts and percentages were found in one of
the surviving Tet2/ recipients compared with four of
the WT recipients, as presented in Figure S7E (table).
To rule out the possibility of age-associated leukemic
transformation contributing to pro-leukemogenic pheno-
type, we transplanted 2 million BM cells from 2- to
3-month-old Tet2/ mice to lethally irradiated age-
matched WT and Tet2/:Flt3ITD/+ recipients and analyzed
them for hematopoietic and non-hematopoietic stromal
components at 36 weeks after transplantation. As shown inic Tet2/ Mice Supports the Expansion of Myeloid Malignant
ring cells to normal WT or preleukemic Tet2/ mice. Bone marrow
into lethally irradiated WT or Tet2/ mice through tail vein and
m and progenitor cells was analyzed 5months after transplantation.
indicated transplanted mice, (ii) Frequency and (iii) number of LSK
+, (ii) Gr1+, and (iii) CD11b+ myeloid cells.
ndicated mice.
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Figure 7. Expansion of Tet2/ Myeloid
Cells but Not B Cells in the Bone Marrow
of Tet2/:Flt3ITD/+ Mice
(A) Schematic showing preleukemic Tet2
cells exposed to normal WT or leukemic
Tet2/:Flt3ITD/+ microenvironment. Two
million bone marrow cells isolated from
Tet2/ mice were transplanted into lethally
irradiated WT or Tet2/:Flt3ITD/+ mice
through tail vein and monitored for disease
progression. Mice were analyzed 6 weeks af-
ter transplantation.
(B) (i) Absolute number of granulocyte/
macrophage progenitor cells (GMP) in the
bone marrow of indicated recipients. (ii)
Representative flow profile of various bone
marrow progenitors in the indicated re-
cipients. CMP, common myeloid progenitor
cells. MEP, megakaryocyte erythroid pro-
genitor cells.
(C–E) (C) Frequency of Gr1+/CD11b+ myeloid
cells in the bone marrow of indicated re-
cipients and (D) frequency of B220+
lymphoid cells in bone marrow of indicated
recipients. (E) Representative flow profile of
myeloid and lymphoid cells in the bone
marrow of recipient mice.
(F and G) (F) Frequency of Gr1+/CD11b+
myeloid cells in the spleen of indicated re-
cipients and (G) frequency of B220+
lymphoid cells in spleen of indicated re-
cipients.
(H) Representative flow profile of myeloid
and lymphoid cells in the spleen of recipient
mice. Student’s t test was performed for
statistical significance (*p < 0.05, n = 3–4
mice in each group).
(I and J) (I) Coculture assay. In brief, bones
from WT and Tet2/:Flt3ITD/+ after flushing
marrow were subjected to collagenase
digestion. Lineage-negative, CD45-negative stromal cells were sorted (4,000 cells/well) directly into 12-well plates containing DMEM,
15% FBS, 100 U penicillin/100 mg streptomycin, and 50 mM 2-mercaptoethanol. OBCs were induced by adding 3 mM b-glycerophosphate
and 10mg/mL L-ascorbic acid phosphate. After 24 h, lineage-negative bone marrow cells fromWT and Tet2/:Flt3ITD/+ mice were added to
the pre-established OBCs and cocultured for another 4 days in the presence of SCF (25 mg/mL), Flt3 ligand (25 mg/mL), and IL-11 (25 mg/
mL). After 4 days, CFU activity in methylcellulose was assessed from all the cells including adherent OBCs, and colonies were counted after
7 days. Statistical analysis was performed by one-way ANOVA with uncorrected Fisher’s test. **p < 0.001, ***p < 0.0001. (J) Two million
bone marrow mononuclear cells from Tet2/: Flt3ITD/ITD mice was transplanted to lethally irradiated 5-month-old WT (n = 4) and Tet2/
(n = 5) mice, and their survival was monitored. Peripheral blood counts from the surviving WT recipients and moribund Tet2/ recipients
are presented in Figure S7E.Figures S7A–S7D, peripheral blood platelet counts are
decreased with significantly increased frequency of CD11b
BM cells, ECs, and OBCs cells in the Tet2/:Flt3ITD/+ recipi-
ents relative to WT controls, suggesting that CD11b, ECs,
and OBCs may all contribute to the malignant phenotype.
Taken together, these data show that when preleukemic
Tet2-deficient BM cells are exposed to leukemic microenvi-ronment driven by Tet2/:Flt3ITD/+ mutations, MPN-like
features are manifested.
DISCUSSION
In addition to genetic and epigenetic changes in BM pro-
genitors, accumulating evidence suggests a role for theStem Cell Reports j Vol. 15 j 95–109 j July 14, 2020 105
BM microenvironment in the development of MPN and
AML (Lane et al., 2009). Using a transgenic BCR/ABL
mouse model of chronic myeloid leukemia (CML),
Schepers et al. (2013) investigated the role of MPN in the
regulation of the endosteal BM niche and found that
leukemic myeloid cells induce the expansion of OBCs
from MSCs and contribute to BM fibrosis. These studies
suggest a contribution of the BM microenvironment to
MPN development, and therapeutic intervention of both
leukemic cells and the BM microenvironment may be
necessary for the complete elimination of leukemia-initi-
ating cells. Thus, understanding the role of BMmicroenvi-
ronment cells in the development of MPN and AML is
necessary for developing better therapies to treat these dis-
eases. Although genetic and in vivo studies on the role of
Tet2 loss in cooperation with Flt3ITD/ITD and in inducing
AML have been conducted (Shih et al., 2015), the in vivo ef-
fects of early and ubiquitous loss ofTet2 followed by expres-
sion of Flt3ITD/ITD in these same cells and their impact on
the function of the BM microenvironment has not previ-
ously been described. First, we found that loss of Tet2 and
constituent activation of Flt3ITD/ITD in BM cells causes a le-
thal AML phenotype with a latency of less than 200 days.
Utilizing a VavCre Tet2//Flt3ITD, Shih et al. (2015) re-
ported a long survival of 600 days. Second, we observed
altered BM microenvironment cell composition including
in the ECs and MSCs in Tet2+/:Flt3ITD/ITD mice. Third, we
observed expansion of pro-inflammatory cytokines and
hyperproliferation of Flt3ITD/ITD donor cells in the preleuke-
mic microenvironment.
In VavCre-driven Tet2/:Flt3ITD/ITD mice, TET2 is deleted
in HSCs specifically and partly on ECs whereas in ourmodel
system, TET2 is deleted globally including MSCs and OBCs,
which play a critical role in the expansion of leukemic cells
and disease progression, thus contributing to a shorter la-
tency. Our results in regard to the composition of microen-
vironment cell composition shows an increase in the fre-
quency of endothelial, mesenchymal, and osteoblastic
lineage cells in preleukemic Tet2/ mice compared with
WTmice, suggesting that the loss of TET2 in these cell types
is a prerequisite for an aggressive lethal AMLphenotype.Our
data are consistent with those of Shih et al. (2015) with
respect to cell-autonomous features including increase in
WBCs, neutrophils, and monocytes, and a reduction in
RBCs. Increase in BM cellularity, expansion of LSK cells
in the BM and spleen, reduction in LT-HSCs, increase
in c-kit/CD11b double-positive myeloid blasts, and
accumulation of CD71, Gr1, and CD11b single-positive
cells in the BM are all features consistent with those
observed by Shih et al. (2015) utilizing a different model
of Tet2/:Flt3ITD/ITD. While loss of Tet2 and expression of
Flt3ITD in BM stem/progenitor cells might be required for
disease initiation in a cell-autonomous manner; AML blasts106 Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020might occupy and alter the BM niche composition leading
to secretion of several pro-inflammatory cytokines, which
are likely to function as growth-promoting factors for the
growth of leukemic cells while repressing normal hemato-
poiesis. Li et al. (2018) showed that conditional deletion of
Tet2 in mesenchymal cells results in accelerated malignant
progression and shortened survival. Other studies (Dong
et al., 2016; Schepers et al., 2013) in CML and MPN model
systems have shown that leukemic myeloid cells induce
the expansion of OBCs from MSCs and secretion of several
pro-inflammatory factors.
While screening AML patients’ plasma Sanchez-Correa
et al. (2013) observed higher levels of IL-5, IL-6, and IL-
10, including an inverse correlation between survival and
plasma levels of IL-6 and IL-10. Several additional studies
have shown that pro-inflammatory cytokines and growth
factors play a crucial role in myeloid malignances by sup-
porting the growth and survival of leukemic cells (Reynaud
et al., 2011; Zhang et al., 2012). In our studies, loss of Tet2
resulted in significant increase in the expression of IL-5 and
IL-6 and a reduction in IL-10 levels, implicating a role for
these cytokines in the pathogenesis of AML driven by
loss of Tet2 and expression of Flt3ITD. IL-5 produced by
mast cells, T cells, and eosinophils and has been shown
to play an important role in eosinophilia (Campbell
et al., 1987; Sanderson, 1992). Our peripheral blood counts
in Tet2/:Flt3ITD/ITD mice also showed increased levels of
eosinophils, correlating with an increase in IL-5 levels,
which could be a consequence of cell-mediated immunity
against progression of lethal AML. Furthermore, elevated
frequency of microenvironmental cells observed in Tet2/
might also contribute to more cytokine production,
thereby contributing to the aggressive AML phenotype
seen in the current study. Several studies (Bochev et al.,
2008; Corcione et al., 2006) have shown that MSCs inhibit
B cell proliferation, differentiation, and immunoglobulin
production. Our data on phenotypic analysis of
Tet2/:Flt3ITD/ITD show reduced frequency of B220/CD19
double-positive cells but not single B220-positive cells in
the BM, suggesting that the elevated numbers of MSCs/
OBCs in the stroma of these animals might be critical for
the maturation of B cells.
Tet2 mutations are shown to be present in both hemato-
poietic and non-hematopoietic malignancies. It is not clear
whether the coexistence of hematopoietic and non-he-
matopoietic cancers occurs in the same individual because
of Tet2 mutations. Given that cellular alterations are inter-
related and occur simultaneously, the extent to which
monocytes, ECs, or OBCs play an important role over
another is not clear. Fuster et al. (2017), and Jaiswal et al.
(2017) showed that loss of Tet2 results in enhanced recruit-
ment of monocytes, which has been linked to accelerated
atherosclerosis through increased production of cytokines
and chemokines. Cull et al. (2017) showed that TET2 re-
strains inflammatory gene expression inmacrophages; sug-
gesting the possibility of altered microenvironment. ECs
play a critical role in HSC maintenance. Duarte et al.
(2018) have shown an increased number of ECs in AML
spleens and that AML progression leads to differential re-
modeling of vasculature by producing pro-inflammatory
and anti-angiogenic cytokines. Cogle et al. (2014) showed
that functional integration of AML cells can either differen-
tiate into endothelial-like cells or fuse with established
endothelium. Osteoblasts play a critical role in the mainte-
nance and expansion of HSC/Ps as well as oncogenic trans-
formation (Dong et al., 2016; Kode et al., 2014, 2016).
In summary, our mouse genetics studies show that loss of
function of Tet2 in cooperation with Flt3ITD/ITD expression
have pathogenic effects on the BM microenvironment and
on resident HSCs in promoting leukemogenesis. Our cocul-
ture data and transplantation data correlate with enhanced
CD11b, EC, and OBC activity and/or numbers in Tet2/:Fl-
t3ITD/+mice (Figures7I andS7B–S7D)suggesting thatCD11b,
ECs, and OBCs also contribute to themalignant phenotype.
Overall, our data support the notion that leukemic cells
alter the BM niche by altering the microenvironmental
cell composition and secretion of pro-inflammatory cyto-
kines, which can promote the growth and survival of
leukemic cells. Therapeutic strategies including reversing
the damage caused to the niche by leukemia cells should
be considered as part of the treatment process, while
considering elimination of fertile ground for disease recur-
rence may be equally essential.EXPERIMENTAL PROCEDURES
Mice
All animal procedures were conducted in accordance with the
Guidelines for the Care and Use of Laboratory Animals and were
approved by the Institutional Animal Care and Use Committee
at Indiana University School of Medicine. The mice were housed
in pathogen-free conditions at the Indiana University Laboratory
Animal Research Center (Indianapolis, IN, USA). Flt3ITD/ITD mice
(Lee et al., 2007) were crossed with Tet2/ mice(Li et al., 2011)
to generate the double-mutantmice.WT (C57BL/6)micewere pro-
cured from the In Vivo Core facility at Indiana University.Flow-Cytometry Analysis
Immunophenotyping was performed as described previously
(Ghosh et al., 2016). Preparation of single-cell suspension and
staining is described in Supplemental Information.Preparation of Stroma and Microenvironmental Cell
Staining
Mesenchymal cells, ECs, and osteoblastic lineage cells from stroma
were stained for flow cytometry following collagenase digestion ofbone fragments as described earlier (Winkler et al., 2010; Schepers
et al., 2013).Acid and Alkaline Phosphatase Assay
TRAP and Vonkossa staining were done on femurs from 22-
week-old from WT, Tet2/, and Tet2/:Flt3ITD/+ mice following
the methods of Erlebacher and Derynck (1996) and Schenk
(1984) at Indiana University School of Medicine Histology
Core Facility. For in vitro experiments CD45-negative, lineage-
negative stromal cells from collagenase digested bone cells
were sorted directly into 12-well plates containing DMEM,
15% fetal bovine serum (FBS), 100 U penicillin/100 mg strepto-
mycin, and 50 mM b-mercaptoethanol. Osteoblasts were
induced by addition of 3 mM b-glycerophosphate and 10 mg/
mL L-ascorbic acid-2-phosphate, and cultured for 2 weeks before
TRAP staining was performed as per manufacturer’s instructions
(Sigma-Aldrich Kit, cat. #387A). Osteoclasts were cultured for
3 weeks and BCIP/NBT (5-bromo-4-chloro-3-indolyl-phos-
phate/nitroblue tetrazolium) staining was performed for alka-
line phosphatase activity following manufacturer’s instructions
(Thermo Scientific, cat. #34042).BM Transplantation
Two million whole BM mononuclear cells isolated from
WT, Tet2+/, Flt3ITD/WT, Flt3ITD/ITD, Tet2+/:Flt3ITD/WT, and
Tet2+/:Flt3ITD/ITD were transplanted into lethally irradiated
C57BL/6 mice through the tail vein and monitored for disease
progression.Serum Cytokine Profiling
Serumwas separated fromperipheral blood and subjected to serum
cytokine bioplex analysis through Eve Technologies (Canada). Re-
sults are expressed as pg/mL of serum.Statistical Analysis
Median values of each group are shown with interquartile
range. Each data point represents the value from individual
mice in their respective groups in Figures 1, 2, 3, 4, and 6. Error
bars indicate the standard error of the mean in Figures 5 and 7.
Statistical analysis was performed using GraphPad version 7 by
one-way ANOVA with uncorrected Fisher’s test for multiple
groups and Student’s t test between two groups. p values in fig-
ures are denoted by *p < 0.05, **p < 0.01, ***p < 0.001, and
****p < 0.0001.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.05.002.
AUTHOR CONTRIBUTIONS
B.R. and R.K. conceived the study, designed experiments, and
wrote the manuscript. B.R., R.S.M., L.R.P., R.P., S.K.P., S.S.B., and
Z.C. carried out the experiments and data analysis. All authors
read and approved the manuscript.Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020 107
ACKNOWLEDGMENTS
We thank RileyChildren’s Foundation for their support to R.K. B.R.
was supported by funds from the Showalter Foundation. This work
was supported by grants from Leukemia and Lymphoma Society
and National Institute of Health, USA.: (R01CA173852,
R01CA134777, R01HL146137, and R01HL140961) to R.K. We
gratefully thank our lab managing scientist Dr. Ping Hu and Tracy
Winkle for their excellent administrative assistance. None of the
authors listed have any financial interest related to this work.
Received: June 19, 2019
Revised: May 1, 2020
Accepted: May 3, 2020
Published: June 4, 2020REFERENCES
Abdel-Wahab, O., and Levine, R.L. (2013). Mutations in epigenetic
modifiers in the pathogenesis and therapy of acute myeloid leuke-
mia. Blood 121, 3563–3572.
Bochev, I., Elmadjian, G., Kyurkchiev, D., Tzvetanov, L., Altan-
kova, I., Tivchev, P., and Kyurkchiev, S. (2008). Mesenchymal
stem cells from human bone marrow or adipose tissue differently
modulate mitogen-stimulated B-cell immunoglobulin production
in vitro. Cell Biol. Int. 32, 384–393.
Cagnetta, A., Adamia, S., Acharya, C., Patrone, F., Miglino, M.,
Nencioni, A., Gobbi, M., and Cea, M. (2014). Role of genotype-
based approach in the clinicalmanagement of adult acutemyeloid
leukemia with normal cytogenetics. Leuk. Res. 38, 649–659.
Campbell, H.D., Tucker,W.Q., Hort, Y., Martinson, M.E.,Mayo, G.,
Clutterbuck, E.J., Sanderson, C.J., and Young, I.G. (1987). Molecu-
lar cloning, nucleotide sequence, and expression of the gene en-
coding human eosinophil differentiation factor (interleukin 5).
Proc. Natl. Acad. Sci. U S A 84, 6629–6633.
Cogle, C.R., Goldman, D.C., Madlambayan, G.J., Leon, R.P., Masri,
A.A., Clark, H.A., Asbaghi, S.A., Tyner, J.W., Dunlap, J., Fan, G.,
et al. (2014). Functional integration of acute myeloid leukemia
into the vascular niche. Leukemia 28, 1978–1987.
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V.,
Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G.L., Pistoia, V.,
et al. (2006). Human mesenchymal stem cells modulate B-cell
functions. Blood 107, 367–372.
Cull, A.H., Snetsinger, B., Buckstein, R., Wells, R.A., and Rauh, M.J.
(2017). Tet2 restrains inflammatory gene expression in macro-
phages. Exp. Hematol. 55, 56–70.e13.
Devos, F.C., Pollaris, L., Cremer, J., Seys, S., Hoshino, T., Ceuppens,
J., Talavera, K., Nemery, B., Hoet, P.H.M., and Vanoirbeek, J.A.J.
(2017). IL-13 is a central mediator of chemical-induced airway hy-
perreactivity in mice. PLoS One 12, e0180690.
Dong, L., Yu, W.M., Zheng, H., Loh, M.L., Bunting, S.T., Pauly, M.,
Huang, G., Zhou, M., Broxmeyer, H.E., Scadden, D.T., et al. (2016).
Leukaemogenic effects of Ptpn11 activatingmutations in the stem
cell microenvironment. Nature 539, 304–308.
Duan, C.W., Shi, J., Chen, J., Wang, B., Yu, Y.H., Qin, X., Zhou,
X.C., Cai, Y.J., Li, Z.Q., Zhang, F., et al. (2014). Leukemia propa-108 Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020gating cells rebuild an evolving niche in response to therapy. Can-
cer Cell 25, 778–793.
Duarte, D., Hawkins, E.D., Akinduro, O., Ang, H., De Filippo, K.,
Kong, I.Y., Haltalli, M., Ruivo, N., Straszkowski, L., Vervoort, S.J.,
et al. (2018). Inhibition of endosteal vascular niche remodeling res-
cues hematopoietic stem cell loss in AML. Cell Stem Cell 22, 64–
77.e6.
Erlebacher, A., and Derynck, R. (1996). Increased expression of
TGF-beta 2 in osteoblasts results in an osteoporosis-like pheno-
type. J. Cell Biol. 132, 195–210.
Forman, S.J., and Rowe, J.M. (2013). Themyth of the second remis-
sion of acute leukemia in the adult. Blood 121, 1077–1082.
Frohling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S.,
Tobis, K., Dohner, H., and Dohner, K. (2002). Prognostic signifi-
cance of activating FLT3 mutations in younger adults (16 to 60
years) with acute myeloid leukemia and normal cytogenetics: a
study of the AML Study Group Ulm. Blood 100, 4372–4380.
Fuster, J.J., MacLauchlan, S., Zuriaga, M.A., Polackal, M.N., Os-
triker, A.C., Chakraborty, R., Wu, C.L., Sano, S., Muralidharan, S.,
Rius, C., et al. (2017). Clonal hematopoiesis associated with TET2
deficiency accelerates atherosclerosis development in mice. Sci-
ence 355, 842–847.
Ghosh, J., Kobayashi, M., Ramdas, B., Chatterjee, A., Ma, P., Mali,
R.S., Carlesso, N., Liu, Y., Plas, D.R., Chan, R.J., et al. (2016).
S6K1 regulates hematopoietic stem cell self-renewal and leukemia
maintenance. J. Clin. Invest. 126, 2621–2625.
Guarnerio, J., Mendez, L.M., Asada, N., Menon, A.V., Fung, J.,
Berry, K., Frenette, P.S., Ito, K., and Pandolfi, P.P. (2018). A non-
cell-autonomous role for Pml in the maintenance of leukemia
from the niche. Nat. Commun. 9, 66.
Harish, A., and Schwartz, S.A. (2020). Targeted anti-IL-5 therapies
and future therapeutics for hypereosinophilic syndrome and rare
eosinophilic conditions. Clin. Rev. Allergy Immunol. https://doi.
org/10.1007/s12016-019-08775-4.
Ichiyama, K., Chen, T., Wang, X., Yan, X., Kim, B.S., Tanaka, S.,
Ndiaye-Lobry, D., Deng, Y., Zou, Y., Zheng, P., et al. (2015). The
methylcytosine dioxygenase Tet2 promotes DNA demethylation
and activation of cytokine gene expression in T cells. Immunity
42, 613–626.
Jaiswal, S., Natarajan, P., Silver, A.J., Gibson, C.J., Bick, A.G.,
Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D.,
et al. (2017). Clonal hematopoiesis and risk of atherosclerotic car-
diovascular disease. N. Engl. J. Med. 377, 111–121.
Kode, A., Manavalan, J.S., Mosialou, I., Bhagat, G., Rathinam, C.V.,
Luo, N., Khiabanian, H., Lee, A., Murty, V.V., Friedman, R., et al.
(2014). Leukaemogenesis induced by an activating beta-catenin
mutation in osteoblasts. Nature 506, 240–244.
Kode, A., Mosialou, I., Manavalan, S.J., Rathinam, C.V., Friedman,
R.A., Teruya-Feldstein, J., Bhagat, G., Berman, E., and Kousteni, S.
(2016). FoxO1-dependent induction of acute myeloid leukemia
by osteoblasts in mice. Leukemia 30, 1–13.
Kottaridis, P.D., Gale, R.E., Frew,M.E., Harrison,G., Langabeer, S.E.,
Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K.,
et al. (2001). The presence of a FLT3 internal tandemduplication in
patients with acute myeloid leukemia (AML) adds important
prognostic information to cytogenetic risk group and response to
the first cycle of chemotherapy: analysis of 854 patients from the
United Kingdom Medical Research Council AML 10 and 12 trials.
Blood 98, 1752–1759.
Lane, S.W., Scadden,D.T., andGilliland,D.G. (2009). The leukemic
stem cell niche: current concepts and therapeutic opportunities.
Blood 114, 1150–1157.
Lee, B.H., Tothova, Z., Levine, R.L., Anderson, K., Buza-Vidas, N.,
Cullen, D.E., McDowell, E.P., Adelsperger, J., Frohling, S., Huntly,
B.J., et al. (2007). FLT3 mutations confer enhanced proliferation
and survival properties to multipotent progenitors in a murine
model of chronic myelomonocytic leukemia. Cancer Cell 12,
367–380.
Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Lar-
son, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., et al. (2010).
DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med.
363, 2424–2433.
Li, R., Zhou, Y., Cao, Z., Liu, L., Wang, J., Chen, Z., Xing,W., Chen,
S., Bai, J., Yuan, W., et al. (2018). TET2 loss dysregulates the
behavior of bone marrow mesenchymal stromal cells and acceler-
ates Tet2(-/-)-driven myeloid malignancy progression. Stem Cell
Reports 10, 166–179.
Li, Z., Cai, X., Cai, C.L., Wang, J., Zhang, W., Petersen, B.E., Yang,
F.C., and Xu, M. (2011). Deletion of Tet2 in mice leads to dysregu-
lated hematopoietic stem cells and subsequent development of
myeloid malignancies. Blood 118, 4509–4518.
Mead, A.J., Neo, W.H., Barkas, N., Matsuoka, S., Giustacchini, A.,
Facchini, R., Thongjuea, S., Jamieson, L., Booth, C.A.G., Fordham,
N., et al. (2017). Niche-mediated depletion of the normal hemato-
poietic stem cell reservoir by Flt3-ITD-inducedmyeloproliferation.
J. Exp. Med. 214, 2005–2021.
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M.,
Jeanne, M., Sala-Torra, O., Radich, J.P., and Passegue, E. (2011).
IL-6 controls leukemic multipotent progenitor cell fate and con-
tributes to chronic myelogenous leukemia development. Cancer
Cell 20, 661–673.
Sanchez-Correa, B., Bergua, J.M., Campos, C., Gayoso, I., Arcos,
M.J., Banas, H.,Morgado, S., Casado, J.G., Solana, R., and Tarazona,
R. (2013). Cytokine profiles in acute myeloid leukemia patients at
diagnosis: survival is inversely correlated with IL-6 and directly
correlated with IL-10 levels. Cytokine 61, 885–891.
Sanderson, C.J. (1992). Interleukin-5, eosinophils, and disease.
Blood 79, 3101–3109.Sato, H., Wheat, J.C., Steidl, U., and Ito, K. (2016). DNMT3A and
TET2 in the pre-leukemic phase of hematopoietic disorders. Front.
Oncol. 6, 187.
Schenk, R. (1984). Preparation of calcified tissue for light micro-
scopy. In Methods of Calcified Tissue Preparation, G.R. Dickson,
ed. (Elsevier), pp. 1–56.
Schepers, K., Pietras, E.M., Reynaud, D., Flach, J., Binnewies, M.,
Garg, T., Wagers, A.J., Hsiao, E.C., and Passegue, E. (2013). Myelo-
proliferative neoplasia remodels the endosteal bonemarrow niche
into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285–299.
Shih, A.H., Jiang, Y.,Meydan, C., Shank, K., Pandey, S., Barreyro, L.,
Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015). Muta-
tional cooperativity linked to combinatorial epigenetic gain of
function in acute myeloid leukemia. Cancer Cell 27, 502–515.
Tefferi, A., Lim, K.H., Abdel-Wahab, O., Lasho, T.L., Patel, J., Pat-
naik, M.M., Hanson, C.A., Pardanani, A., Gilliland, D.G., and Lev-
ine, R.L. (2009). Detection of mutant TET2 in myeloid malig-
nancies other than myeloproliferative neoplasms: CMML, MDS,
MDS/MPN and AML. Leukemia 23, 1343–1345.
Tian, X., Xu, Y., Yin, J., Tian, H., Chen, S., Wu, D., and Sun, A.
(2014). TET2 gene mutation is unfavorable prognostic factor in
cytogenetically normal acute myeloid leukemia patients with
NPM1+ and FLT3-ITD- mutations. Int. J. Hematol. 100, 96–104.
Wakita, S., Yamaguchi, H., Omori, I., Terada, K., Ueda, T., Manabe,
E., Kurosawa, S., Iida, S., Ibaraki, T., Sato, Y., et al. (2013).Mutations
of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at
diagnosis may induce FLT3-ITD at relapse in de novo acute
myeloid leukemia. Leukemia 27, 1044–1052.
Weissmann, S., Alpermann, T., Grossmann, V., Kowarsch, A., Na-
darajah, N., Eder, C., Dicker, F., Fasan, A., Haferlach, C., Haferlach,
T., et al. (2012). Landscape of TET2mutations in acutemyeloid leu-
kemia. Leukemia 26, 934–942.
Winkler, I.G., Sims, N.A., Pettit, A.R., Barbier, V., Nowlan, B., Hel-
wani, F., Poulton, I.J., van Rooijen, N., Alexander, K.A., Raggatt,
L.J., et al. (2010). Bonemarrowmacrophagesmaintain hematopoi-
etic stem cell (HSC) niches and their depletion mobilizes HSCs.
Blood 116, 4815–4828.
Yu, H., Sui, Y., Wang, Y., Sato, N., Frey, B., Xia, Z., Waldmann, T.A.,
and Berzofsky, J. (2015). Interleukin-15 constrainsmucosal T help-
er 17 cell generation: influence of mononuclear phagocytes. PLoS
One 10, e0143001.
Zhang, B., Ho, Y.W., Huang, Q., Maeda, T., Lin, A., Lee, S.U., Hair,
A., Holyoake, T.L., Huettner, C., and Bhatia, R. (2012). Altered
microenvironmental regulation of leukemic and normal stem cells
in chronic myelogenous leukemia. Cancer Cell 21, 577–592.Stem Cell Reports j Vol. 15 j 95–109 j July 14, 2020 109
